Docoh
Loading...

ADGI Adagio Therapeutics

News

From Benzinga Pro
Stocks That Hit 52-Week Lows On Friday
14 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Friday's session, 445 companies made new 52-week lows.
30 Stocks Moving In Friday's Mid-Day Session
14 Jan 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers ATI Physical Therapy, Inc. (NYSE: ATIP) shares gained 25.2% to $3.8050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.50 to $5.
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
13 Jan 22
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Adagio's COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies
13 Jan 22
Biotech, Long Ideas, News, Health Care, Small Cap, FDA, Movers, Trading Ideas, General
Adagio Therapeutics Inc (NASDAQ: ADGI) shares gain during the premarket session after recent findings showing that ADG20 has neutralization activity against the omicron variant.
20 Stocks Moving in Thursday's Pre-Market Session
13 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday.
Adagio Therapeutics Granted U.S. Patent #11,220,536 'Compounds specific to coronavirus S protein and uses thereof'
11 Jan 22
News
View Patent here
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
6 Jan 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Morgan Stanley Downgrades Adagio Therapeutics to Underweight, Lowers Price Target to $6
6 Jan 22
News, Downgrades, Price Target, Analyst Ratings
Morgan Stanley analyst Matthew Harrison downgrades Adagio Therapeutics (NASDAQ:ADGI) from Equal-Weight to Underweight and lowers the price target from $11 to $6.
50 Biggest Movers From Yesterday
23 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares surged 53.4% to settle at $16.31 on Wednesday.
32 Stocks Moving In Wednesday's Mid-Day Session
22 Dec 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares surged 31.7% to $2.41 after the company announced it was awarded a multiple award blanket purchase agreement by the United States Customs and Border Protection worth up to $90 million over five years.
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021
22 Dec 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
10 Biggest Price Target Changes For Wednesday
22 Dec 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Barclays lifted the price target on FactSet Research Systems Inc. (NYSE: FDS) from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.
20 Stocks Moving in Wednesday's Pre-Market Session
22 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers BioRestorative Therapies, Inc. (NASDAQ: BRTX) rose 48.1% to $6.77 in pre-market trading after the company entered into a Master Service Agreement with PRC Clinical, a contract research organization (CRO), to conduct BioRestorative's Phase 2 trial.
Jefferies Downgrades Adagio Therapeutics to Hold, Lowers Price Target to $10
22 Dec 21
News, Downgrades, Price Target, Analyst Ratings
Jefferies downgrades Adagio Therapeutics (NASDAQ:ADGI) from Buy to Hold and lowers the price target from $46 to $10.
26 Stocks Moving in Tuesday's Pre-Market Session
21 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
63 Biggest Movers From Friday
20 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15 price target.
20 Stocks Moving in Friday's Pre-Market Session
17 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Genfit SA (NASDAQ: GNFT) rose 47.5% to $4.90 in pre-market trading. Ipsen and GENFIT reported an exclusive licensing agreement for Elafibranor.
58 Biggest Movers From Yesterday
17 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price target from Jefferies.
Watching Adagio Therapeutics Shares Following US Patent & Trademark Office Abstract For Co.'s 'COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF'
16 Dec 21
News, Legal
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220210388067%22.PGNR.&OS=DN/20210388067
What's Going On With Adagio Therapeutics Stock Today?
16 Dec 21
News, Price Target, Small Cap, Analyst Ratings, Movers, Trading Ideas
Adagio Therapeutics Inc (NASDAQ: ADGI) is soaring on abnormally-high volume Thursday as traders discuss the stock on various social media platforms.

Press releases

From Benzinga Pro
Thinking about buying stock in Adagio Therapeutics, Vyne Therapeutics, PetVivo, BTCS Inc, or Mattel?
13 Jan 22
Opinion, Press Releases
NEW YORK, Jan. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADGI, VYNE, PETV, BTCS, and MAT.
Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron
12 Jan 22
Health Care, Press Releases, General
Recent Publications by Several Independent Laboratories Show ADG20 Has Neutralizing Activity with Potency Comparable to Other Antibodies that Retain Activity Against Omicron Multiple Efforts Underway to Address Omicron
Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
6 Jan 22
News, Health Care, Press Releases
WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based
Thinking about buying stock in Adagio Therapeutics, Wireless Telecom, BRF S.A., Energy Focus, or Vicarious Surgical?
17 Dec 21
Opinion, Press Releases
NEW YORK, Dec. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADGI, WTT, BRFS, EFOI, and RBOT.
Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies
17 Dec 21
Press Releases
BOSTON, Dec. 17, 2021 /PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund
Thinking about buying stock in Luminar Technologies, Cleveland-Cliffs, Pulmatrix, Adagio Therapeutics, or Ensysce Biosciences?
15 Dec 21
Fintech, Opinion, Press Releases
NEW YORK, Dec. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LAZR, CLF, PULM, ADGI, and ENSC.
Thinking about buying stock in SeaChange, Nuverra Environmental Solutions, Adagio Therapeutics, American Virtual Cloud Technologies, or Robinhood Markets?
14 Dec 21
Opinion, Press Releases
NEW YORK, Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SEAC, NES, ADGI, AVCT, and HOOD.
Thinking about buying stock in Adagio Therapeutics, Pioneer Power Solutions, ImmunoGen, Athersys, or First Wave BioPharma?
30 Nov 21
Small Cap, Opinion, Press Releases
NEW YORK, Nov. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADGI, PPSI, IMGN, ATHX, and FWBI.
Thinking about buying stock in Adagio Therapeutics, 180 Life Sciences, InMed Pharmaceuticals, Beyondspring, or Inovio Pharmaceuticals?
29 Nov 21
Opinion, Press Releases
NEW YORK, Nov. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADGI, ATNF, INM, BYSI, and INO.
Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro
29 Nov 21
News, Press Releases
Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing ADG20 EUA submissions planned for prevention and treatment of COVID-19 in mid-2022 Inventory build continues in
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Support Rapid Advancement and Commercial Readiness of ADG20 for COVID-19
22 Nov 21
News, Management, Press Releases
WALTHAM, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
15 Nov 21
Earnings, Press Releases
FDA Feedback Supports Planned Emergency Use Authorization (EUA) Submission for ADG20 for Prevention of COVID-19; Interim Clinical Data Package from EVADE Prevention Trial to Support EUA Submission Expected in Second
Adagio Therapeutics to Participate in Upcoming Investor Conferences
10 Nov 21
News, Press Releases
WALTHAM, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based